Marketing authorisation has been recommended in the EU by an EMA committee for Sixmo (buprenorphine) as a substitution treatment for opioid dependence.
The post Long-lasting opioid treatment recommended by an EMA committee appeared first on European Pharmaceutical Review.
Original Article: Long-lasting opioid treatment recommended by an EMA committee